Anti-type2-Antibodies Specifically Inhibit Murine Asthma Features Induced By Intranasal Application of IL-5 and IL-13

The type2 cytokines IL-5 and IL-13 are central to asthma pathogenesis, and innovative therapeutic approaches focus on strategic inhibition of these mediators.